These findings suggest that limonin could overcome the limitations of current treatments, such as systemic side effects of mTOR inhibitors, and serve as a promising alternative therapeutic candidate for psoriasis and related inflammatory skin diseases. This evidence concerns the gene MTOR and psoriasis.